AKRO - Akero Therapeutics, Inc.
About Akero Therapeutics, Inc. (https://www.akerotx.com)
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Andrew Cheng | President, Chief Executive Officer & Director | 1967 | $1,097,600 USD |
| William R. White | Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporate Development | 1973 | $739,500 USD |
| Timothy Rolph | Co-Founder & Chief Scientific Officer | 1954 | $722,315 USD |
| Catriona Yale | Executive Vice President & Chief Development Officer | 1972 | $716,300 USD |
| Jonathan Young | Co-Founder, Executive Vice President, Chief Operating Officer & Secretary | 1970 | $710,500 USD |
| Scott A. Gangloff | Chief Technical Officer | 1974 | $558,641 USD |
| John J. Schembri | Senior Vice President & Head of Finance | 1962 | – |
| Patrick Lamy | Senior Vice President of Commercial Strategy | 1973 | – |
| Thomas Ross | Senior Vice President & Head of Legal | – | – |